Chapter

Hormone replacement therapy in patients with a prior history of breast cancer

Gilbert G. Fareau and Rena Vassilopoulou-Sellin

in Endocrine Therapies in Breast Cancer

Published on behalf of Oxford University Press

ISBN: 9780199218141
Published online May 2011 | e-ISBN: 9780199606993 | DOI: http://dx.doi.org/10.1093/med/9780199218141.003.0008

Series: Oxford Oncology Library

Hormone replacement therapy in patients with a prior history of breast cancer

Show Summary Details

Preview

• Women with a history of breast cancer are more likely to be exposed to oestrogen deficiency, and may experience oestrogen deficiency for longer durations than women in the general population. • For some women, the symptoms of oestrogen deficiency can be prolonged, extremely debilitating, and severely compromise quality of life. • Although hormone replacement therapy (HRT) remains the most effective agent for the treatment of climacteric symptoms, the evidence no longer favours its routine use in postmenopausal women. Alternative approaches to correct or palliate the sequelae of oestrogen deficiency should be explored. • In the absence of definitive safety data, we continue to counsel our patients that a history of breast cancer remains a relative contraindication to HRT; we parti-cularly discourage patients with recently treated, exten-sive, or hormonally responsive disease from using HRT. • If menopausal symptoms or skeletal morbidity com-promise a breast cancer survivor’s health or quality of life, oestrogen use may be considered following indi-vidualized discussion with the patient. In these cases, the lowest effective dose of oestrogen should be prescribed for the shortest tolerable duration.

Chapter.  3781 words. 

Subjects: Clinical Oncology

Full text: subscription required

How to subscribe Recommend to my Librarian

Buy this work at Oxford University Press »

Users without a subscription are not able to see the full content. Please, subscribe or login to access all content.